Assessing the Health and Economic Outcomes of a 9-Valent HPV Vaccination Program in the United Kingdom

Assessing the Health and Economic Outcomes of a 9-Valent HPV Vaccination Program in the United Kingdom

**Background:** The United Kingdom (UK) switched from using the 4-valent human papillomavirus (HPV) vaccine (Gardasil®) to the 9-valent vaccine (Gardasil 9®) in 2021. **Objective:** To estimate and compare the health and economic outcomes of 2 HPV vaccination programs in the UK targeting girls and...

Full description

Bibliographic Details
Main Authors: Kwame Owusu-Edusei, Cody Palmer, Olga Ovcinnikova, Giampiero Favato, Vincent Daniels
Format: Article
Language:English
Published: Columbia Data Analytics, LLC 2022-06-01
Series:Journal of Health Economics and Outcomes Research
Online Access:https://jheor.org/article/34721-assessing-the-health-and-economic-outcomes-of-a-9-valent-hpv-vaccination-program-in-the-united-kingdom

Internet

https://jheor.org/article/34721-assessing-the-health-and-economic-outcomes-of-a-9-valent-hpv-vaccination-program-in-the-united-kingdom

Similar Items